



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/626,275	07/24/2003	Ernest J. Lee	PC28017	9606
23913	7590	05/29/2008	EXAMINER	
PFIZER INC			SCHLIENTZ, NATHAN W	
Steve T. Zelson				
150 EAST 42ND STREET			ART UNIT	PAPER NUMBER
5TH FLOOR - STOP 49				
NEW YORK, NY 10017-5612			1616	
			MAIL DATE	DELIVERY MODE
			05/29/2008	PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/626,275	LEE ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Nathan W. Schlientz	1616	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 07 December 2007.
- 2a) This action is **FINAL**.                    2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 1-27 is/are pending in the application.
- 4a) Of the above claim(s) 26 and 27 is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) 1-25 is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All    b) Some \* c) None of:
1. Certified copies of the priority documents have been received.
  2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)          | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ .                                    |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)          | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ .  | 6) <input type="checkbox"/> Other: _____ .                        |

## **DETAILED ACTION**

### ***Status of Claims***

Claims 26 and 27 have been withdrawn. As a result, claims 1-25 are examined herein on the merits for patentability. No claim is allowed at this time.

### ***Withdrawn Rejections***

Rejections and/or objections not reiterated from the previous Office Action are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set of rejections and/or objections presently being applied to the instant application.

### ***Claim Rejections - 35 USC § 112***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

1. Claim 2 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. In particular, claim 2 states, "or a test substantially equivalent thereto." However, the instant specification does not provide any guidance with respect to determine what types of tests are substantially equivalent to the *in vitro* dissolution profile disclosed.

***Double Patenting***

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

1. Claims 1-16 and 18-25 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over Claims 1-23 of copending Application No. 10/626,166. Although the conflicting claims are not identical, they are not patentably distinct from each other because both sets of claims are drawn to a pharmaceutical composition comprising pramipexole and a pharmaceutically acceptable excipient. Accordingly, the scope of the copending claims overlap and thus they are obvious variants of one another.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

***Response to Arguments***

Applicant's Remarks filed 07 December 2007 have been fully considered but they are not persuasive. Applicants argue on page 6 that the present claims are directed to sustained-release pramipexole compositions that exhibit a particular "*in vitro* release profile" or "*in vivo* release profile". However, Example 10 of the '166 application discloses that the compositions claimed have a dissolution profile wherein at 2 hours the coated tablet showed no more than 20% dissolution. Therefore, the compositions of the '166 application inherently possess the *in vitro* dissolution profile of the instant claims.

Applicants also argue on page 6 that the claims of the '166 application comprise a starch having a particular tensile strength, whereas the claims of the present application do not require the inclusion of the starch limitation.

However, the claims of the present application are drawn to a composition "comprising" pramipexole and a pharmaceutically acceptable excipient, wherein the composition displays a certain *in vitro* and/or *in vivo* property. The transitional term "comprising", which is synonymous with "including," "containing," or "characterized by," is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. See MPEP 2111.03. Therefore, the claims of the present application do not exclude the presence of a starch having a particular tensile strength. Also, the examiner directs attention to Example 10 of the '166 application wherein it is disclosed that the compositions of their claims inherently possess the dissolution profile wherein less than 20% of the pramipexole is dissolved at 2 hours. Therefore, the compositions

of the '166 application would inherently possess the properties as claimed in the present application.

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1,148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
  2. Ascertaining the differences between the prior art and the claims at issue.
  3. Resolving the level of ordinary skill in the pertinent art.
  4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
1. Claims 1-25 are rejected under 35 U.S.C. 103(a) as being unpatentable over U.S. Patent Application Publication No. 2002/0103240 (Pospisilik '240) in view of U.S. Patent No. 6,197,339 (Ju) (cited in the IDS filed 22 September 2003).

**Applicant claims:**

Applicants claim an orally deliverable composition comprising pramipexole and at least one pharmaceutically acceptable excipient wherein the composition exhibits an *in vitro* release profile such that at 2 hours no more than about 20% has dissolved, or an *in vivo* absorption profile such that the time to reach a mean of 20% absorption is greater

than 2 hours and/or the time to reach 40% absorption is greater than 4 hours. Applicants also claim the composition above in the form of discrete dosage units sufficient to provide a daily dosage in one to a small plurality of dosage units administered at one time.

**Determination of the scope and content of the prior art**

**(MPEP 2141.01)**

Pospisilik '240 teaches controlled release pellet or tablet compositions may be produced using pramipexole comprising a mixture of pramipexole salt, a suitable filler, such as microcrystalline cellulose, and a suitable release controlling agent comprising water and/or a water-insoluble macromolecular substance such as an acrylate polymer or a modified cellulose ([0064]). Pospisilik '240 further teaches that pramipexole is commercially available as the dihydrochloride salt ([0004]).

**Ascertainment of the difference between the prior art and the claims**

**(MPEP 2141.02)**

Pospisilik '240 does not teach the controlled release pramipexole to have an *in vitro* release profile wherein at 2 hours no more than 20% pramipexole has dissolved, or an *in vivo* absorption profile wherein the time to reach a mean of 20% absorption is greater than about 2 hours and/or the time to reach a mean of 40% absorption is greater than about 4 hours, as instantly claimed.

However, Ju teaches a sustained release formulation comprising 0.3-16% R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1) (sumanirole maleate), 60-69% starch and 30-40% hydroxypropylmethylcellulose,

wherein the starch is preferably pregelatinized starch and the HPMC is preferably HPMC 2208 USP 4,000 cps or HPMC 2910 USP 4,000 cps (col. 2, ll. 1-60).

Pramipexole and sumanirole maleate are both dopamine D<sub>2</sub> receptor agonists useful in the treatment of Parkinson's disease (instant specification pages 1 and 2, paragraphs [0003] and [0007]; and Ju col. 1, ll. 14-24).

Pospisilik '240 also does not teach the controlled release pramipexole wherein the pramipexole is in the form of a dosage unit that is given as a daily dose in one to a small plurality of dosage units administered at one time, as instantly claimed.

However, Ju teaches that the exact dosage and frequency of administration depends on the severity of the condition being treated, the weight, general physical condition of the particular patient, and other medication the individual may be taking, as is well-known to those skilled in the art and can be more accurately determined by measuring the blood level or concentration of the drug in the patient's blood and/or the patient's response to the particular condition being treated (col. 3, ll. 45-54).

### **Finding of *prima facie* obviousness**

### **Rational and Motivation (MPEP 2142-43)**

Therefore, it would have been *prima facie* obvious for one skilled in the art at the time of the invention to formulate the controlled release pellet or tablet compositions comprising pramipexole dihydrochloride salt, as taught by Pospisilik '240, further comprising 60-69% starch and 30-40% hydroxypropylmethylcellulose, as reasonably taught by Ju. It would also have been *prima facie* obvious for one of ordinary skill in the

art to determine the appropriate dosage unit and administration frequency, as reasonably taught by Ju.

It is noted that Ju does not teach the *in vitro* release profile and *in vivo* absorption profile that result from starch and HPMC sustained release formulations. However, the formulations comprise the same starch and HPMC compounds in the same amounts as the compounds of the instant application (instant specification pages 10-11, paragraphs [0052]-[0059]). Therefore, the sustained release formulations would inherently possess the *in vitro* release profile and *in vivo* absorption profile as instantly claimed.

The examiner respectfully points out the following from MPEP 2112: “The discovery of a previously unappreciated property of a prior art composition, or of a scientific explanation for the prior art’s functioning, does not render the old composition patentably new to the discoverer.” *Atlas Powder Co. v. Ireco Inc.*, 190 F.3d 1342, 1347, 51 USPQ2d 1943, 1947 (Fed. Cir. 1999). Thus the claiming of a new use, new function or unknown property which is inherently present in the prior art does not necessarily make the claim patentable. *In re Best*, 562 F.2d 1252, 1254, 195 USPQ 430, 433 (CCPA 1977). In *In re Crish*, 393 F.3d 1253, 1258, 73 USPQ2d 1364, 1368 (Fed. Cir. 2004), the court stated that “just as the discovery of properties of a known material does not make it novel, the identification and characterization of a prior art material also does not make it novel.”

From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole would have been *prima facie* obvious to

one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

2. Claims 1-18 and 20-22 are rejected under 35 U.S.C. 103(a) as being unpatentable over U.S. Patent Application Publication No. 2004/0068119 (Pospisilik '119) in view of U.S. Patent No. 6,197,339 (Ju).

**Applicant claims:**

Applicants claim an orally deliverable composition comprising pramipexole and at least one pharmaceutically acceptable excipient wherein the composition exhibits an *in vitro* release profile such that at 2 hours no more than about 20% has dissolved, or an *in vivo* absorption profile such that the time to reach a mean of 20% absorption is greater than 2 hours and/or the time to reach 40% absorption is greater than 4 hours. Applicants also claim the composition above in the form of discrete dosage units sufficient to provide a daily dosage in one to a small plurality of dosage units administered at one time.

**Determination of the scope and content of the prior art**

**(MPEP 2141.01)**

Pospisilik '119 teaches controlled release pellet or tablet compositions may be produced using pramipexole comprising a mixture of pramipexole salt, a suitable filler, such as microcrystalline cellulose, and a suitable release controlling agent comprising water and/or a water-insoluble macromolecular substance such as an acrylate polymer

or a modified cellulose ([0061]). Pospisilik '119 further teaches that pramipexole is commercially available as the dihydrochloride salt ([0004]).

**Ascertainment of the difference between the prior art and the claims**

**(MPEP 2141.02)**

Pospisilik '119 does not teach the controlled release pramipexole to have an *in vitro* release profile wherein at 2 hours no more than 20% pramipexole has dissolved, or an *in vivo* absorption profile wherein the time to reach a mean of 20% absorption is greater than about 2 hours and/or the time to reach a mean of 40% absorption is greater than about 4 hours, as instantly claimed.

However, Ju teaches a sustained release formulation comprising 0.3-16% R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1) (sumanirole maleate), 60-69% starch and 30-40% hydroxypropylmethylcellulose, wherein the starch is preferably pregelatinized starch and the HPMC is preferably HPMC 2208 USP 4,000 cps or HPMC 2910 USP 4,000 cps (col. 2, ll. 1-60).

Pramipexole and sumanirole maleate are both dopamine D<sub>2</sub> receptor agonists useful in the treatment of Parkinson's disease (instant specification pages 1 and 2, paragraphs [0003] and [0007]; and Ju col. 1, ll. 14-24).

Pospisilik '119 also does not teach the controlled release pramipexole wherein the pramipexole is in the form of a dosage unit that is given as a daily dose in one to a small plurality of dosage units administered at one time, as instantly claimed.

However, Ju teaches that the exact dosage and frequency of administration depends on the severity of the condition being treated, the weight, general physical

condition of the particular patient, and other medication the individual may be taking, as is well-known to those skilled in the art and can be more accurately determined by measuring the blood level or concentration of the drug in the patient's blood and/or the patient's response to the particular condition being treated (col. 3, ll. 45-54).

**Finding of *prima facie* obviousness**

**Rational and Motivation (MPEP 2142-43)**

Therefore, it would have been *prima facie* obvious for one skilled in the art at the time of the invention to formulate the controlled release pellet or tablet compositions comprising pramipexole dihydrochloride salt, as taught by Pospisilik '119, further comprising 60-69% starch and 30-40% hydroxypropylmethylcellulose, as reasonably taught by Ju. It would also have been *prima facie* obvious for one of ordinary skill in the art to determine the appropriate dosage unit and administration frequency, as reasonably taught by Ju.

It is noted that Ju does not teach the *in vitro* release profile and *in vivo* absorption profile that result from starch and HPMC sustained release formulations. However, the formulations comprise the same starch and HPMC compounds in the same amounts as the compounds of the instant application (instant specification pages 10-11, paragraphs [0052]-[0059]). Therefore, the sustained release formulations would inherently possess the *in vitro* release profile and *in vivo* absorption profile as instantly claimed.

The examiner respectfully points out the following from MPEP 2112: "The discovery of a previously unappreciated property of a prior art composition, or of a scientific explanation for the prior art's functioning, does not render the old composition

patentably new to the discoverer." *Atlas Powder Co. v. Ireco Inc.*, 190 F.3d 1342, 1347, 51 USPQ2d 1943, 1947 (Fed. Cir. 1999). Thus the claiming of a new use, new function or unknown property which is inherently present in the prior art does not necessarily make the claim patentable. *In re Best*, 562 F.2d 1252, 1254, 195 USPQ 430, 433 (CCPA 1977). In *In re Crish*, 393 F.3d 1253, 1258, 73 USPQ2d 1364, 1368 (Fed. Cir. 2004), the court stated that "just as the discovery of properties of a known material does not make it novel, the identification and characterization of a prior art material also does not make it novel."

From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

### **Contact Information**

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nathan W. Schlientz whose telephone number is 571-272-9924. The examiner can normally be reached on 8:30 AM to 5:00 PM, Monday through Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johann Richter can be reached on 571-272-0646. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1616

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

NWS

/Mina Haghigian/  
Primary Examiner  
Art Unit 1616